Formuepleje Competitors

Stocks . Denmark . 
Stock . Formuepleje Limittellus
FPILIM Stock  DKK 294.32  6.05  2.10%   
Formuepleje Limittellus competes with Novo Nordisk, Nordea Bank, DSV Panalpina, AP Mller, and AP Mller; as well as few others. Analyzing Formuepleje Limittellus competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Formuepleje Limittellus to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Formuepleje Limittellus Correlation with its peers.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Formuepleje Limittellus competition on your existing holdings.
  
Hype
Prediction
LowEstimatedHigh
293.56294.32295.08
Details
Intrinsic
Valuation
LowRealHigh
234.70235.46323.75
Details
Naive
Forecast
LowNextHigh
291.67292.44293.20
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
283.32289.81296.30
Details

Formuepleje Limittellus Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Formuepleje Limittellus and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Formuepleje and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Formuepleje Limittellus does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
MAERSK-A
+ 1.0
MAERSK-B
GMAB
+ 0.93
NOVO-B
VWS
+ 0.85
NOVO-B
GMAB
+ 0.77
VWS
CARL-B
+ 0.74
VWS
CARL-B
+ 0.73
ORSTED
  
High negative correlations   
GMAB
- 0.89
DSV
DSV
- 0.81
NOVO-B
CARL-B
- 0.71
MAERSK-B
CARL-B
- 0.7
MAERSK-A
GMAB
- 0.67
MAERSK-B
MAERSK-B
- 0.66
NOVO-B

Risk-Adjusted Indicators

There is a big difference between Formuepleje Stock performing well and Formuepleje Limittellus Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Formuepleje Limittellus' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
NOVO-B  1.47 (0.35) 0.00 (0.53) 0.00 
 0.00 
 2.66 
(3.23)
 9.15 
NDA-DK  0.84 (0.04)(0.12) 0.00  0.97 
(0.97)
 1.53 
(1.58)
 7.98 
DSV  1.15  0.27  0.18  1.05  0.73 
(1.44)
 2.66 
(1.43)
 12.28 
MAERSK-B  2.09  0.32  0.04 (0.25) 2.26 
(2.38)
 4.03 
(3.61)
 14.21 
MAERSK-A  1.96  0.30  0.03 (0.20) 2.18 
(2.22)
 3.84 
(3.29)
 14.30 
ORSTED  1.67  0.20 (0.03)(0.04) 2.80 
(1.73)
 4.06 
(3.27)
 18.80 
VWS  2.01 (0.52) 0.00  0.65  0.00 
 0.00 
 3.32 
(4.63)
 17.28 
GMAB  0.99 (0.34) 0.00 (1.46) 0.00 
 0.00 
 1.53 
(2.83)
 8.81 
COLO-B  1.20 (0.11) 0.00 (0.12) 0.00 
 0.00 
 2.11 
(2.35)
 6.72 
CARL-B  1.22 (0.08) 0.00 (0.25) 0.00 
 0.00 
 2.68 
(2.59)
 7.87 
All Fundamental Data

Formuepleje Limittellus Competitive Analysis

The better you understand Formuepleje Limittellus competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Formuepleje Limittellus' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Formuepleje Limittellus' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
FPILIM NOVO-B NDA-DK DSV MAERSK-B MAERSK-A ORSTED VWS GMAB COLO-B
 2.10 
 294.32 
Formuepleje
 4.03 
 750.90 
Novo
 0.43 
 79.16 
Nordea
 0.40 
 1,504 
DSV
 1.31 
 12,005 
MAERSK-B
 0.70 
 11,540 
MAERSK-A
 1.41 
 388.50 
Orsted
 0.22 
 99.48 
Vestas
 2.49 
 1,484 
Genmab
 2.11 
 891.60 
Coloplast
Market Volatility
(90 Days Market Risk)
Very steady
Very steady
Very steady
Very steady
Very steady
Very steady
Very steady
Very steady
Very steady
Very steady
Market Performance
(90 Days Performance)
Good
Very Weak
Very Weak
Good
OK
OK
Weak
Very Weak
Very Weak
Very Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
Low
Low
Low
Low
Low
Low
Low
Low
Low
Low
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Fairly Valued
Under Valued
Over Valued
Over Valued
Over Valued
Fairly Valued
Fairly Valued
Fairly Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Strong Hold
Hold
Hold
Strong Buy
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Cautious Hold
Hold
Current Ratio
N/A
1.06
N/A
1.01
1.37
1.13
1.95
1.02
15.42
1.12
Net Asset
N/A
241.26 B
594.84 B
159.04 B
93.68 B
93.68 B
314.14 B
20.09 B
24.63 B
34.96 B
Profit Margin
0.91
0.31
0.37
0.0746
0.36
0.36
0.11
-0.11
0.47
0.2
EBITDA
N/A
76.8 B
N/A
24.6 B
37.18 B
37.18 B
32.72 B
(545 M)
4.24 B
7.23 B
Operating Margin
0.91
0.43
0.5
0.11
0.38
0.38
0.0855
-0.0721
0.38
0.3
Current Valuation
808.86 M
2.1 T
464.06 B
269.42 B
207.26 B
207.26 B
323.55 B
217.13 B
186.33 B
203.46 B
Price To Book
N/A
27.51
1.18
3.03
0.63
0.62
5.54
7.51
7.86
22.36
Retained Earnings
N/A
36.07 B
N/A
7.4 B
31.8 B
31.08 B
N/A
2.57 B
N/A
4.7 B
Current Asset
N/A
46.38 B
N/A
17 B
11.27 B
10.73 B
N/A
6.33 B
N/A
6.01 B
Five Year Return
N/A
2.45
N/A
0.37
2.16
2.24
N/A
1.29
N/A
2.29
Beta
0.94
0.33
0.9
1.08
1.37
1.37
0.56
1.16
0.67
0.21
Number Of Employees
N/A
54.39 K
28.27 K
76.28 K
110 K
110 K
8.03 K
28.44 K
1.56 K
14.5 K
Shares Outstanding
3.37 M
1.72 B
3.62 B
216.26 M
7.38 M
10.11 M
420.23 M
1.01 B
65.96 M
194.31 M
Cash Flow From Operations
4.97 M
78.89 B
21.98 B
26.85 B
34.48 B
34.48 B
11.92 B
(195 M)
2.23 B
5.1 B
Annual Yield
N/A
0.0115
0.0727
0.0051
0.28
0.17
0.0212
0.0017
N/A
0.0252
Total Debt
N/A
20.77 B
N/A
21.4 B
3.77 B
3.77 B
60.45 B
1.96 B
378 M
16.36 B
Return On Equity
0.21
0.72
0.11
0.24
0.53
0.53
0.17
-0.41
0.24
0.75
Z Score
N/A
64.2
N/A
8.8
43.2
42.6
2.4
64.8
N/A
6.0
Return On Asset
0.13
0.22
0.0062
0.0982
0.23
0.23
0.0242
-0.0328
0.1
0.17
Book Value Per Share
177.07
37.1
8.63
329.73
3632.12
3632.12
217.83
3.03
408.67
27.81
Current Liabilities
N/A
41.07 B
N/A
15.02 B
9.61 B
9.29 B
N/A
5.26 B
N/A
4.78 B
Total Asset
N/A
241.26 B
594.84 B
159.04 B
93.68 B
93.68 B
314.14 B
20.09 B
24.63 B
34.96 B
Debt To Equity
N/A
0.21
N/A
0.56
54.2
62.8
43.1
0.5
0.018
43.4
Target Price
N/A
975.48
93.87
1387.35
20832.7
12250.0
745.0
497.32
3239.73
954.18
Last Dividend Paid
N/A
12.4
0.8
6.5
623.0
623.0
13.5
N/A
N/A
20.0
Shares Owned By Institutions
N/A
38.87
60.54
49.3
53.82
58.88
24.45
46.64
49.9
25.53
Market Capitalization
782.56 M
2.24 T
302.44 B
281.93 B
274.76 B
270.01 B
269.87 B
212.24 B
185.21 B
175.43 B
Price To Earning
N/A
37.49
N/A
56.94
58.43
53.81
13.2
27.15
34.78
42.1
Price To Earnings To Growth
N/A
2.0
9.0
3.73
0.35
0.34
6.36
2.36
1.19
3.38
Price To Sales
6.46
12.16
28.93
0.95
3.13
3.04
2.15
14.28
17.0
7.79
Net Income
106.24 M
55.52 B
3.6 B
17.57 B
29.2 B
29.2 B
15.13 B
(1.57 B)
3.01 B
4.71 B
Earnings Per Share
31.41
24.44
6.96
76.2
11054.63
11054.63
34.6
-3.89
83.21
21.76
Shares Owned By Insiders
N/A
N/A
0.72
17.0
5.3
19.93
55.0
0.06
N/A
35.0
Revenue
127.25 M
176.95 B
9.79 B
235.66 B
81.53 B
81.53 B
126.09 B
14.49 B
8.48 B
22.58 B
Working Capital
N/A
5.31 B
N/A
1.98 B
1.66 B
1.44 B
N/A
1.07 B
N/A
1.23 B
Cash And Equivalents
N/A
27.22 B
N/A
2.03 B
5 B
4.96 B
25.31 B
1.92 B
18.08 B
620 M
Cash Per Share
N/A
11.83
N/A
9.22
242.74
246.39
60.26
1.9
276.57
2.92
Gross Profit
116.55 M
148.51 B
9.72 B
52.15 B
36.73 B
36.73 B
35.11 B
118 M
8.48 B
15.53 B
Day Typical Price
294.32
740.73
79.05
1505.17
11905.0
11466.67
388.23
98.81
1472.17
886.87
Accumulation Distribution
N/A
0.0406
0.0213
0.0161
0.0332
0.0276
0.0199
0.0253
0.0229
0.0204
Market Facilitation Index
N/A
30.5
1.7
24.5
400.0
320.0
7.8
2.52
34.0
18.2
Daily Balance Of Power
9.2 T
0.9541
(0.20)
(0.24)
0.3875
0.25
0.6923
0.0873
1.058824
1.010989
Period Momentum Indicator
6.05
29.1
(0.34)
(6.00)
155.0
80.0
5.4
0.22
36.0
18.4
Rate Of Daily Change
1.02
1.04
1.0
1.0
1.01
1.01
1.01
1.0
1.02
1.02
Day Median Price
294.32
735.65
78.99
1505.75
11855.0
11430.0
388.1
98.48
1466.5
884.5
Price Action Indicator
3.03
29.8
N/A
(4.75)
227.5
150.0
3.1
1.11
35.0
16.3
Relative Strength Index
16.41
10.6
39.91
31.98
67.83
69.75
34.77
70.74
80.81
25.15
Coefficient Of Variation
704.03
(702.78)
14639.16
587.24
1159.34
1255.62
4443.64
(477.01)
(486.30)
(3,556)
Mean Deviation
0.5657
1.47
0.841
1.15
2.09
1.96
1.67
2.01
0.9922
1.2
Jensen Alpha
0.0192
(0.35)
(0.04)
0.2703
0.3215
0.3048
0.2035
(0.52)
(0.34)
(0.11)
Total Risk Alpha
(0.02)
(0.59)
(0.19)
0.0137
(0.20)
(0.21)
(0.36)
(1.11)
(0.54)
(0.29)
Sortino Ratio
(0.03)
N/A
(0.12)
0.1759
0.0404
0.0304
(0.03)
N/A
N/A
N/A
Downside Variance
0.4414
N/A
0.9822
1.1
5.68
5.28
8.15
N/A
N/A
N/A
Standard Deviation
0.7585
1.94
1.21
1.85
2.63
2.52
2.56
2.98
1.46
1.51
Kurtosis
1.31
0.5255
6.66
12.56
0.5195
0.8693
9.13
6.21
3.39
(0.07)
Potential Upside
1.18
2.66
1.53
2.66
4.03
3.84
4.06
3.32
1.53
2.11
Treynor Ratio
0.1502
(0.53)
(0)
1.05
(0.25)
(0.20)
(0.04)
0.6482
(1.46)
(0.12)
Maximum Drawdown
4.02
9.15
7.98
12.28
14.21
14.3
18.8
17.28
8.81
6.72
Variance
0.5753
3.75
1.46
3.43
6.93
6.34
6.55
8.9
2.14
2.28
Market Risk Adjusted Performance
0.1602
(0.52)
0.005
1.06
(0.24)
(0.19)
(0.03)
0.6582
(1.45)
(0.11)
Risk Adjusted Performance
0.1088
(0.10)
0.0089
0.1365
0.0732
0.068
0.0243
(0.15)
(0.15)
(0.02)
Skewness
0.3913
(0.24)
1.57
2.88
0.204
0.2168
(1.61)
(1.80)
(0.65)
0.2538
Semi Deviation
0.5176
N/A
0.9729
0.7276
2.26
2.18
2.8
N/A
N/A
N/A
Information Ratio
(0.03)
(0.21)
(0.10)
0.0997
0.0366
0.0277
(0.03)
(0.25)
(0.30)
(0.11)
Value At Risk
(1.00)
(3.23)
(1.58)
(1.43)
(3.61)
(3.29)
(3.27)
(4.63)
(2.83)
(2.35)
Expected Short fall
(0.67)
N/A
(0.97)
(1.44)
(2.38)
(2.22)
(1.73)
N/A
N/A
N/A
Downside Deviation
0.6644
N/A
0.9911
1.05
2.38
2.3
2.85
N/A
N/A
N/A
Semi Variance
0.2679
N/A
0.9464
0.5294
5.11
4.76
7.83
N/A
N/A
N/A

Formuepleje Limittellus Competition Performance Charts

Five steps to successful analysis of Formuepleje Limittellus Competition

Formuepleje Limittellus' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Formuepleje Limittellus in relation to its competition. Formuepleje Limittellus' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Formuepleje Limittellus in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Formuepleje Limittellus' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Formuepleje Limittellus, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Formuepleje Limittellus position

In addition to having Formuepleje Limittellus in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Large & Mid Caps ETFs Thematic Idea Now

Large & Mid Caps ETFs
Large & Mid Caps ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Large & Mid Caps ETFs theme has 41 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Large & Mid Caps ETFs Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in Formuepleje Stock

Formuepleje Limittellus financial ratios help investors to determine whether Formuepleje Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Formuepleje with respect to the benefits of owning Formuepleje Limittellus security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY